Oryn Therapeutics is a clinical stage biotechnology company developing Orynotides, a new class of bioinspired macrocyclic peptides as therapeutics for autoimmune and chronic inflammatory diseases, infectious diseases, and oncology.
Orynotides are highly stable cyclic peptides with demonstrated preclinical efficacy in models of each of the listed disease categories.